Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Novavax Inc (NVAX)

Novavax Inc (NVAX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 544,417
  • Shares Outstanding, K 139,953
  • Annual Sales, $ 983,710 K
  • Annual Income, $ -545,060 K
  • 60-Month Beta 1.59
  • Price/Sales 0.57
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade NVAX with:

Options Overview Details

View History
  • Implied Volatility 91.98% ( -1.60%)
  • Historical Volatility 40.75%
  • IV Percentile 17%
  • IV Rank 47.42%
  • IV High 177.22% on 07/05/23
  • IV Low 15.11% on 11/28/23
  • Put/Call Vol Ratio 1.00
  • Today's Volume 2,815
  • Volume Avg (30-Day) 8,927
  • Put/Call OI Ratio 0.87
  • Today's Open Interest 324,659
  • Open Int (30-Day) 318,385

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -1.04
  • Number of Estimates 5
  • High Estimate -0.85
  • Low Estimate -1.48
  • Prior Year -3.41
  • Growth Rate Est. (year over year) +69.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.81 +2.10%
on 04/18/24
5.16 -24.54%
on 03/19/24
-1.25 (-24.32%)
since 03/18/24
3-Month
3.53 +10.12%
on 02/05/24
6.05 -35.70%
on 02/27/24
-0.22 (-5.35%)
since 01/18/24
52-Week
3.53 +10.12%
on 02/05/24
11.36 -65.76%
on 05/09/23
-5.41 (-58.17%)
since 04/18/23

Most Recent Stories

More News
Better Buy: Bluebird Bio Vs. Novavax

Who wins this face-to-face between two beaten-down biotechs?

BLUE : 0.9530 (-1.07%)
NVAX : 3.89 (unch)
Down 60% From Its 52-Week High, Is Novavax Stock a Buy?

Is there still too much risk surrounding this business?

PFE : 25.39 (-0.12%)
NVAX : 3.89 (unch)
1 Beaten-Down Stock to Buy and 1 to Avoid Like the Plague

These stocks could move in very different directions over the long run.

TDOC : 13.18 (+0.30%)
NVAX : 3.89 (unch)
1 Beaten-Down Stock That's Still Not Worth Buying

For this biotech, a rebound seems far too unlikely.

NVAX : 3.89 (unch)
Two Beaten-Down Stocks That Could Soar 170% and 630%, Respectively, According to Wall Street

Could these biotech companies still win in the vaccine market and beyond?

NVAX : 3.89 (unch)
OCGN : 1.3200 (-8.33%)
Is Novavax a Buy Now?

The stock has dropped 98% over the past three years.

MRNA : 102.00 (-1.39%)
PFE : 25.39 (-0.12%)
NVAX : 3.89 (unch)
1 of the Biggest Risks Facing Novavax Has Now Been Resolved: Is Now the Time to Buy the Stock?

Can the stock's recent rally continue?

NVAX : 3.89 (unch)
Novavax: Q4 Earnings Snapshot

Novavax: Q4 Earnings Snapshot

NVAX : 3.89 (unch)
Has Novavax Just Solved Its Biggest Problem?

The biotech company recently settled a dispute with a major customer.

NVAX : 3.89 (unch)
Better Bull Market Buy: Novavax vs. Pfizer

Bull markets usually favor stocks with promising growth prospects.

NVAX : 3.89 (unch)
PFE : 25.39 (-0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Novavax, Inc. is a biotechnology company engaged in developing innovative vaccines to prevent serious infectious diseases. The company is also developing proprietary immune stimulating saponin-based adjuvants, namely Matrix-M, which already enhanced immune responses and were well-tolerated in multiple...

See More

Key Turning Points

3rd Resistance Point 4.15
2nd Resistance Point 4.07
1st Resistance Point 3.98
Last Price 3.89
1st Support Level 3.81
2nd Support Level 3.72
3rd Support Level 3.63

See More

52-Week High 11.36
Fibonacci 61.8% 8.37
Fibonacci 50% 7.45
Fibonacci 38.2% 6.52
Last Price 3.89
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar